MDAI

This article is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

MDAI
Chemical Nomenclature
Common names	MDAI
Substitutive name	5,6-Methylenedioxy-2-aminoindane
Systematic name	6,7-Dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine
Class Membership
Psychoactive class	Entactogen
Chemical class	Aminoindane / MDxx
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Oral Dosage Threshold 40 mg Light 40 - 100 mg Common 100 - 175 mg Strong 175 - 300 mg Heavy 300 mg + Duration Total 4 - 6 hours Onset 20 - 40 minutes Come up 30 - 60 minutes Peak 2 - 2.5 hours Offset 1 - 2 hours DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions
MAOIs
Serotonin releasers
SSRIs
5-HTP

MDAI (5,6-Methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) in vitro and produces entactogen effects in humans similar to that of MDMA.

Chemistry

The chemical structure of MDAI is indirectly derived from that of the illicit drug MDA, but the alpha-methyl group of the alkylamino amphetamine side chain has been bound back to the benzene nucleus to form an indane ring system, which changes its pharmacological properties substantially.[1]

Pharmacology

The chemical structure of MDAI is indirectly derived from that of the illicit drug MDA, but the alpha-methyl group of the alkyl]]amino amphetamine side chain has been bound back to the benzene nucleus to form an indane ring system, which changes its pharmacological properties substantially.